文献速递淋巴瘤造血干细胞移植与细胞治疗

预处理方案强度对接受异基因移植的外周T细胞淋巴瘤、间变性大细胞淋巴瘤和血管免疫母细胞性T细胞淋巴瘤患者结局的影响

Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
PubMed 文献 · Br J Haematol · 2022-02-02

该研究纳入2008-2019年间向国际血液和骨髓移植研究中心报告的803例接受异基因造血干细胞移植的成人T细胞非霍奇金淋巴瘤患者,比较减低强度/非清髓性预处理(RIC/NMA,n=545)与清髓性预处理(MAC,n=258)的结局。多变量分析显示两组总生存、非复发死亡、进展/复发风险和治疗失败均无显著差异,RIC/NMA组3-4级急性移植物抗宿主病风险显著更低。结论认为预处理强度与T细胞非霍奇金淋巴瘤异基因移植后结局无关。

要点

  • RIC/NMA组与MAC组总生存无显著差异(HR=1.01,95%CI 0.79-1.29;p=0.95)。
  • RIC/NMA组3-4级急性GVHD风险显著低于MAC组(HR=0.67,95%CI 0.46-0.99;p=0.04)。
  • 在化学难治患者中,RIC/NMA与MAC方案的总生存、治疗失败、复发或非复发死亡均无差异。

核心结论

  • 研究发现预处理强度与T细胞非霍奇金淋巴瘤异基因造血干细胞移植后的结局无关。

研究设计与样本

  • 回顾性队列研究,纳入2008-2019年间向国际血液和骨髓移植研究中心报告的803例接受异基因造血干细胞移植的成人T细胞非霍奇金淋巴瘤患者(年龄18-65岁),其中MAC组258例,RIC/NMA组545例。

主要发现

  • 两组患者性别、种族和体能评分无显著差异;RIC/NMA组接受外周血移植物、造血细胞移植特异性合并症指数(HCT-CI)≥3和化学敏感性疾病者显著多于MAC组。
  • 多变量分析显示RIC/NMA组与MAC组总生存无显著差异(HR=1.01,95%CI 0.79-1.29;p=0.95)。
  • 非复发死亡(HR=0.85,95%CI 0.61-1.19;p=0.34)、进展/复发风险(HR=1.29,95%CI 0.98-1.70;p=0.07)和治疗失败(HR=1.14,95%CI 0.92-1.41;p=0.23)在两组间均无显著差异。
  • 相对于MAC,RIC/NMA与3-4级急性移植物抗宿主病风险显著降低相关(HR=0.67,95%CI 0.46-0.99;p=0.04)。
  • 在化学难治患者中,RIC/NMA与MAC方案的总生存、治疗失败、复发或非复发死亡均无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There have been no large studies comparing reduced-intensity/non-myeloablative conditioning (RIC/NMA) to myeloablative conditioning (MAC) regimens in T-cell non-Hodgkin lymphoma (T-NHL) patients undergoing allogeneic transplant (allo-HCT). A total of 803 adults with peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma (age 18-65 years), undergoing allo-HCT between 2008-2019 and reported to the Center for International Blood and Marrow Transplant Research with either MAC (n = 258) or RIC/NMA regimens (n = 545) were evaluated. There were no significant differences between the two cohorts in terms of patient sex, race and performance scores. Significantly more patients in the RIC/NMA cohort had peripheral blood grafts, haematopoietic cell transplantation-specific comorbidity index (HCT-CI) of ≥3 and chemosensitive disease compared to the MAC cohort. On multivariate analysis, overall survival (OS) was not significantly different in the RIC/NMA cohort compared to the MAC cohort (hazard ratio (HR) = 1.01, 95% confidence interval (CI) = 0.79-1.29; p = 0.95). Similarly, non-relapse mortality (NRM) (HR = 0.85, 95% CI = 0.61-1.19; p = 0.34), risk of progression/relapse (HR = 1.29; 95% CI = 0.98-1.70; p = 0.07) and therapy failure (HR = 1.14; 95% CI = 0.92-1.41, p = 0.23) were not significantly different between the two cohorts. Relative to MAC, RIC/NMA was associated with a significantly lower risk of grade 3-4 acute graft-versus-host disease (HR = 0.67; 95% CI = 0.46-0.99, p = 0.04). Among chemorefractory patients, there was no difference in OS, therapy failure, relapse, or NRM between RIC/NMA and MAC regimens. In conclusion, we found no association between conditioning intensity and outcomes after allo-HCT for T-cell NHL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Savani M, Ahn KW, Chen Y, et al. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. Br J Haematol. 2022. PMID: 35106754. doi:10.1111/bjh.18052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。